Skip to main navigation
  • News & Investors

    News & Investors

    • Press Releases
    • Financial Events
    • Scientific Presentations
    • Corporate Governance
    • Financial Information
    • Stock Information
    • Analyst Coverage
    • Request Information
    • Investor FAQs
    • Investor Contact
  • Contact Us
Celsion
  • TECHNOLOGY
    • LTSL
    • TheraPlas
    • TheraSilence
  • PRODUCTS
    • ThermoDox
    • GEN-1
  • PIPELINE
    • Clinical Studies
    • Pre-clinical Programs
  • DISEASES
  • PUBLICATIONS
  • ABOUT US
    • Leadership
    • Board of Directors
    • Corporate Governance
Select Page

Press Releases

    Investor Relations

    • News & Investors
    • Press Releases
    • Financial Events
    • Scientific Presentations
    • Corporate Governance
    • Financial Information
    • Stock Information
    • Analyst Coverage
    • Request Information
    • Investor FAQs
    • Investor Contact

Press Releases

Company News

Date Title and Summary Additional Formats
Toggle Summary Mar 23, 2020 Celsion’s GEN-1 Immunotherapy Receives Orphan Drug Designation from the European Medicines Agency
Approval Adds 10 Years of Market Exclusivity Following Marketing Authorization in Europe LAWRENCEVILLE, N.J. , March 23, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, today announced the European Medicines Agency (EMA) Committee for Orphan
View HTML
PDF Version
Toggle Summary Mar 19, 2020 Celsion Corporation to Hold Year-End 2019 Financial Results Conference Call on Thursday, March 26, 2020
  Company to Provide Update on its Phase III OPTIMA Study in Primary Liver Cancer  and its Phase I/II OVATION 2 Study in Ovarian Cancer LAWRENCEVILLE, N.J. , March 19, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss
View HTML
PDF Version
Toggle Summary Mar 19, 2020 Celsion Announces Highly Encouraging Initial Clinical Results from the Phase I Portion of the Phase I/II OVATION 2 Study with GEN-1 in Patients with Advanced Ovarian Cancer
  R0 (Complete) Surgical Resection Rates for Patients Randomized to GEN-1 Treatment Arm Compare Favorably to Patients Receiving Neoadjuvant Chemotherapy Only Company to Proceed with Phase II Portion of the OVATION 2 Study After All Phase I Patients Have Completed Their Full Treatment Regimen (up to
View HTML
PDF Version
Toggle Summary Mar 3, 2020 Celsion CEO Issues Letter to Stockholders
LAWRENCEVILLE, N.J. , March 03, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, announces that Michael H. Tardugno , the company’s chairman, president and chief executive officer, issued the following letter to stockholders.
View HTML
PDF Version
Toggle Summary Feb 28, 2020 Celsion Corporation Prices $4.8 Million Registered Direct Offering
LAWRENCEVILLE, NJ , Feb. 28, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced it has entered into securities purchase agreements with institutional investors for the purchase and sale of 4,571,428 shares of the Company’s common stock, par
View HTML
PDF Version
Toggle Summary Feb 6, 2020 Celsion Corporation Announces DSMB has Confirmed Initial Safety of Weekly GEN-1 Dosing at 100 mg/m² in 15 Randomized Patients with Advanced Ovarian Cancer
  Phase 2 Portion Will Continue After Patients Have Completed Their Full Treatment Regimen of up to 17 doses of GEN-1 plus Standard Chemotherapy LAWRENCEVILLE, N.J. , Feb. 06, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation  (NASDAQ: CLSN) today announced that the independent Data Safety Monitoring
View HTML
PDF Version
Toggle Summary Feb 4, 2020 Principal Investigator Professor Riccardo Lencioni Presents Celsion ThermoDox® Trial Data at SPECTRUM 2020 Interventional Oncology Conference
Company reaffirms its projection for second pre-planned interim efficacy analysis for Phase III OPTIMA Study in the second quarter of 2020 LAWRENCEVILLE, N.J. , Feb. 04, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , an oncology drug-development company, announces that Prof.
View HTML
PDF Version
Toggle Summary Dec 18, 2019 Celsion’s New Subsidiary in China to Serve as Beachhead for Commercializing ThermoDox® in China and Southeast Asia
Memorandum of Understanding completed with Chinese government officials in the Yuhang district of Hangzhou , China’s biotech hub, to develop and commercialize innovative cancer therapies starting with ThermoDox ® . Agreement includes numerous financial and non-financial incentives including grants
View HTML
PDF Version
Toggle Summary Dec 17, 2019 Celsion Receives $2.0 Million Allocation Through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program
  Non-Dilutive Funding Strengthens Balance Sheet; Proceeds Equate to More Than $0.08 Per Share Assures Funding Through Major Company Events; Company Provides Guidance on the Timing of Upcoming Development Milestones for the Phase III OPTIMA Study and the Phase I/II OVATION 2 Study LAWRENCEVILLE,
View HTML
PDF Version
Toggle Summary Nov 14, 2019 Celsion Corporation Reports Third Quarter 2019 Financial Results and Provides Business Update
Independent Data Monitoring Committee (iDMC) Unanimously Recommends Continuation of Phase III OPTIMA Study at First Pre-Planned Efficacy Analysis Independent Data Safety Monitoring Board (DSMB) Unanimously Recommends Continuation of Phase I Portion of OVATION 2 Study         Strong Balance Sheet
View HTML
PDF Version

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 3
  • Current page 4
  • Page 5
  • Page 6
  • …
  • Next page Next
  • Last page Last

    Shareholder Tools

    • Printed Materials
    • Email Alerts
    • Downloads
    • RSS
    • Print
    • Search

    • Facebook
    • Google
    • LinkedIn
    • Twitter
    • RSS

Home

Technology

Products

Pipeline

Disease

Publications

News & Investors

About Us

Careers

Privacy Policy

    ThermoDox is a registered trademark of Celsion Corporation.
    TheraPlas and TheraSilence are trademarks of Celsion Corporation.
    Avastin is a registered trademark of Genentech, Inc.
    Copyright © 2021 Celsion Corporation. All rights reserved.

    Share This
    • Twitter
    • Google+
    • Facebook
    • LinkedIn